Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Other Accumulated Expenses (2016 - 2017)

Historic Other Accumulated Expenses for Dare Bioscience (DARE) over the last 5 years, with Q2 2017 value amounting to $120000.0.

  • Dare Bioscience's Other Accumulated Expenses fell 8307.48% to $120000.0 in Q2 2017 from the same period last year, while for Jun 2017 it was $120000.0, marking a year-over-year decrease of 8307.48%. This contributed to the annual value of $575000.0 for FY2016, which is 3488.11% down from last year.
  • Latest data reveals that Dare Bioscience reported Other Accumulated Expenses of $120000.0 as of Q2 2017, which was down 8307.48% from $300000.0 recorded in Q1 2017.
  • Dare Bioscience's Other Accumulated Expenses' 5-year high stood at $974000.0 during Q1 2015, with a 5-year trough of $120000.0 in Q2 2017.
  • For the 5-year period, Dare Bioscience's Other Accumulated Expenses averaged around $525933.3, with its median value being $558000.0 (2015).
  • As far as peak fluctuations go, Dare Bioscience's Other Accumulated Expenses surged by 31271.19% in 2015, and later crashed by 8307.48% in 2017.
  • Quarter analysis of 5 years shows Dare Bioscience's Other Accumulated Expenses stood at $379000.0 in 2013, then soared by 74.93% to $663000.0 in 2014, then surged by 33.18% to $883000.0 in 2015, then crashed by 34.88% to $575000.0 in 2016, then tumbled by 79.13% to $120000.0 in 2017.
  • Its last three reported values are $120000.0 in Q2 2017, $300000.0 for Q1 2017, and $575000.0 during Q4 2016.